Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics
Concert Pharmaceuticals, Inc. (CNCE)
Today's Latest Price: $7.95 USD
0.07 (0.89%)
Updated Dec 10 4:00pm
Add CNCE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
CNCE Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CNCE is 0 -- better than only 7.05% of US stocks.
- With a price/sales ratio of 6,336.7, Concert Pharmaceuticals Inc has a higher such ratio than 99.95% of stocks in our set.
- As for revenue growth, note that CNCE's revenue has grown -99.98% over the past 12 months; that beats the revenue growth of only 0.44% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Concert Pharmaceuticals Inc are SAGE, TGTX, VHC, CBMG, and ZYNE.
- CNCE's SEC filings can be seen here. And to visit Concert Pharmaceuticals Inc's official web site, go to www.concertpharma.com.
CNCE Daily Price Range
CNCE 52-Week Price Range
CNCE Stock Price Chart More Charts
CNCE Price/Volume Stats
| Current price | $7.95 | 52-week high | $17.83 |
| Prev. close | $7.88 | 52-week low | $5.36 |
| Day low | $7.73 | Volume | 128,800 |
| Day high | $7.98 | Avg. volume | 218,466 |
| 50-day MA | $6.59 | Dividend yield | N/A |
| 200-day MA | $10.22 | Market Cap | 189.54M |
Concert Pharmaceuticals, Inc. (CNCE) Company Bio
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts.
Top Stories View All
Why Investors Should be Bullish About GW Pharmaceuticals (GWPH)
Why I Believe Facebook (FB) is Headed Higher
Best & Worst Performing Stock Industries for December 10, 2019
Best & Worst Performing Small Cap Stocks for December 10, 2019
Best & Worst Performing Mid Cap Stocks for December 10, 2019
View All Top Stories
Loading social stream, please wait...